
Vertex Pharmaceuticals Incorporated
VRTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 3, 2026 | Cantor Fitzgerald | Carter Gould | $619.00(+16%) | $535.41 | StreetInsider |
| Nov 3, 2026 | Wells Fargo | Mohit Bansal | $650.00(+18%) | $553.15 | StreetInsider |
| Oct 8, 2026 | RBC Capital | $576.00(+15%) | $502.62 | TheFly | |
| Sep 28, 2026 | UBS | $615.00(+16%) | $528.04 | TheFly | |
| Sep 23, 2026 | Jefferies | Akash Tewari | $640.00(+24%) | $514.99 | StreetInsider |
| Sep 22, 2026 | H.C. Wainwright | Andrew Fein | $641.00(+23%) | $519.67 | StreetInsider |
| Sep 1, 2026 | Morgan Stanley | Terence Flynn | $665.00(+21%) | $547.65 | TheFly |
| Sep 1, 2026 | Goldman Sachs | $653.00(+20%) | $544.52 | TheFly | |
| Aug 11, 2026 | Bernstein | Jeffrey Walch | $608.00(+15%) | $530.29 | StreetInsider |
| Aug 10, 2026 | Wolfe Research | Andy Chen | $562.00(+8%) | $522.78 | StreetInsider |
| Aug 5, 2026 | Truist Financial | $565.00(+16%) | $488.56 | TheFly | |
| Aug 5, 2026 | Barclays | $617.00(+29%) | $478.70 | TheFly | |
| Aug 4, 2026 | Cantor Fitzgerald | $595.00(+26%) | $470.72 | TheFly | |
| Aug 4, 2026 | Canaccord Genuity | $442.00(-6%) | $470.72 | TheFly | |
| Aug 4, 2026 | Stifel Nicolaus | $500.00(+6%) | $470.72 | TheFly | |
| Jul 13, 2026 | UBS | $585.00(+21%) | $481.70 | TheFly | |
| Jul 13, 2026 | Truist Financial | $560.00(+17%) | $479.01 | TheFly | |
| Jul 7, 2026 | RBC Capital | $570.00(+8%) | $529.59 | TheFly | |
| Jul 7, 2026 | Robert W. Baird | $350.00(-34%) | $529.59 | TheFly | |
| May 27, 2026 | Truist Financial | Danielle Brill | $542.00(+24%) | $435.93 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Barclays | maintain | Overweight | Nov 4, 2026 |
| JP Morgan | maintain | Overweight | Nov 3, 2026 |
| Goldman Sachs | maintain | Buy | Nov 3, 2026 |
| Morgan Stanley | maintain | Overweight | Nov 3, 2026 |
| Scotiabank | maintain | Sector Outperform | Nov 3, 2026 |
| UBS | maintain | Buy | Nov 3, 2026 |
| TD Cowen | maintain | Buy | Nov 3, 2026 |
| Wells Fargo | maintain | Overweight | Nov 3, 2026 |
| RBC Capital | maintain | Outperform | Nov 3, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Nov 3, 2026 |
| Stifel | maintain | Hold | Nov 3, 2026 |
| RBC Capital | maintain | Outperform | Oct 8, 2026 |
| UBS | maintain | Buy | Sep 28, 2026 |
| Truist Securities | maintain | Buy | Aug 5, 2026 |
| Barclays | maintain | Overweight | Aug 5, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 4, 2026 |
| TD Cowen | maintain | Buy | Aug 4, 2026 |
| Canaccord Genuity | maintain | Hold | Aug 4, 2026 |
| UBS | maintain | Buy | Jul 13, 2026 |
| Truist Securities | maintain | Buy | Jul 13, 2026 |
| Baird | maintain | Underperform | Jul 7, 2026 |
| RBC Capital | maintain | Outperform | Jul 7, 2026 |
| Barclays | maintain | Overweight | May 6, 2026 |
| RBC Capital | maintain | Outperform | May 5, 2026 |
| Bernstein | maintain | Outperform | May 5, 2026 |
Earnings History
Next report: Feb 11, 2027 · EPS est. $4.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 2, 2026 | $4.76 | $4.82 | $3.44B | $3.42B |
| Aug 3, 2026 | $4.73 | $4.74 | $3.33B | $3.23B |
| May 4, 2026 | $4.47 | $4.24 | $2.99B | $2.99B |
| Feb 12, 2026 | $5.03 | $5.11 | $3.19B | $3.18B |
| Nov 3, 2025 | $4.80 | $4.57 | $3.08B | $3.06B |
| Aug 4, 2025 | $4.52 | $4.29 | $2.96B | $2.91B |
| May 5, 2025 | $4.06 | $4.25 | $2.77B | $2.86B |
| Feb 10, 2025 | $3.98 | $4.02 | $2.91B | $2.78B |
News
Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,962 shares of the pharmaceutical company's stock, valued at approximately $3,117,000. A number of other hedge funds
AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,080 shares of the pharmaceutical company's stock after selling 7,521 shares during the period. AIA Group Ltd's holdings
VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.
Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 121.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,055 shares of the pharmaceutical company's stock
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.
Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Executive VP & Chief Commercial Officer Charles Wagner - Executive VP, COO & CFO Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Salveen Richter - Goldma…
Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.8 per share a year ago.
Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition,” said Reshma Kewalramani, M.D., Ch.
Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.
VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.